Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 798,988
  • Shares Outstanding, K 53,337
  • Annual Sales, $ 193,120 K
  • Annual Income, $ 25,210 K
  • 60-Month Beta 0.29
  • Price/Sales 4.12
  • Price/Cash Flow 27.81
  • Price/Book 1.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.12
  • Number of Estimates 2
  • High Estimate 0.20
  • Low Estimate 0.04
  • Prior Year 0.19
  • Growth Rate Est. (year over year) -36.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.63 +18.61%
on 10/14/19
15.37 -2.54%
on 11/13/19
+2.27 (+17.86%)
since 10/11/19
3-Month
12.32 +21.62%
on 10/10/19
15.55 -3.67%
on 08/19/19
-0.07 (-0.47%)
since 08/13/19
52-Week
11.83 +26.63%
on 07/25/19
33.44 -55.20%
on 12/03/18
-7.59 (-33.63%)
since 11/13/18

Most Recent Stories

More News
Coherus Bioscien has the Best Relative Performance in the Biotechnology Industry (CHRS , VNDA , ATRA , EPZM , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ATRA : 13.10 (+0.81%)
CHRS : 19.20 (+4.18%)
VNDA : 14.98 (+0.33%)
Vanda: 3Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported third-quarter net income of $100.4 million.

VNDA : 14.98 (+0.33%)
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019.

VNDA : 14.98 (+0.33%)
Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday, November 6, 2019, after the market...

VNDA : 14.98 (+0.33%)
Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following Ms. Ward's appointment, Vanda's...

VNDA : 14.98 (+0.33%)
Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs

Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics (ASHG) conference on October 19, 2019,...

VNDA : 14.98 (+0.33%)
Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve...

VNDA : 14.98 (+0.33%)
Look for Shares of Vanda Pharmaceut to Potentially Rebound after Yesterday's 2.16% Sell Off

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $12.68 to a high of $13.06. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of...

VNDA : 14.98 (+0.33%)
Spectrum Pharmac is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SPPI , VNDA , MNTA , ESPR , CHRS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

MNTA : 16.46 (+0.06%)
SPPI : 8.25 (+1.85%)
VNDA : 14.98 (+0.33%)
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.

MRK : 84.82 (+0.83%)
VNDA : 14.98 (+0.33%)
ACOR : 1.93 (-2.53%)
MNLO : 4.68 (-2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade VNDA with:

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 15.68
1st Resistance Point 15.33
Last Price 14.98
1st Support Level 14.67
2nd Support Level 14.36

See More

52-Week High 33.44
Fibonacci 61.8% 25.18
Fibonacci 50% 22.63
Fibonacci 38.2% 20.09
Last Price 14.98
52-Week Low 11.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar